

# CITATION REPORT

List of articles citing

**Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques**

**DOI: 10.1371/journal.ppat.1005042**  
**PLoS Pathogens, 2015, 11, e1005042.**

**Source:** <https://exaly.com/paper-pdf/61053138/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
140	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. <b>2015</b> , 7, 5115-32		37
139	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , <b>2015</b> , 89, 12189-210	6.6	66
138	Immunity to HIV. <b>2016</b> , 342-354		1
137	AIDS Vaccines. <b>2016</b> , 401-422		1
136	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005817	7.6	89
135	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <b>2016</b> , 14, 97-111		29
134	Naturally Occurring Fc-Dependent Antibody From HIV-Seronegative Individuals Promotes HIV-Induced IFN- $\gamma$ Production. <b>2016</b> , 6, 37493		1
133	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <b>2016</b> , 197, 2726-37		25
132	Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <b>2016</b> , 15, 823-834		41
131	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. <b>2016</b> , 35, 217-26		7
130	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. <i>Journal of Virology</i> , <b>2016</b> , 90, 10993-11006	6.6	29
129	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <b>2016</b> , 12, 208-218		45
128	Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240. <b>2016</b> , 6, 36685		18
127	Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences. <b>2016</b> , 11, 546-554		26
126	The first 24 h: targeting the window of opportunity for antibody-mediated protection against HIV-1 transmission. <b>2016</b> , 11, 561-568		7
125	Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. <b>2016</b> , 30, 2551-2553		5
124	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <b>2016</b> , 113, E3413-22		132

123	Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in Mucus. <b>2016</b> , 2, 82-92		20
122	New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. <b>2016</b> , 15, 1015-27		6
121	Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. <b>2016</b> , 9, 1549-1558		41
120	IgG Fc variant cross-reactivity between human and rhesus macaque FcBs. <b>2017</b> , 9, 455-465		14
119	HIV antibodies for treatment of HIV infection. <b>2017</b> , 275, 313-323		46
118	Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	46
117	Polyvalent vaccine approaches to combat HIV-1 diversity. <b>2017</b> , 275, 230-244		33
116	Survivors Remorse: antibody-mediated protection against HIV-1. <b>2017</b> , 275, 271-284		23
115	Lessons learned from human HIV vaccine trials. <b>2017</b> , 12, 216-221		25
114	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	5
113	Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals. <b>2017</b> , 12, 209-215		9
112	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , <b>2017</b> , 8, 15711	17.4	94
111	Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process. <i>Retrovirology</i> , <b>2017</b> , 14, 13	3.6	5
110	Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5 $\alpha$ -Restrictive Macaques. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	58
109	Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. <b>2017</b> , 7, 12655		35
108	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. <b>2017</b> , 170, 637-648.e10		93
107	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	21
106	NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients. <b>2017</b> , 441, 24-30		8

105	Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. <b>2017</b> , 215, S152-S159		17
104	Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1033	8.4	10
103	Non-Neutralizing Antibodies Directed against HIV and Their Functions. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1590	8.4	33
102	Increasing the Clinical Potential and Applications of Anti-HIV Antibodies. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1655	8.4	16
101	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	25
100	Passive and active antibody studies in primates to inform HIV vaccines. <b>2018</b> , 17, 127-144		27
99	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	33
98	Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	30
97	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. <b>2018</b> , 10,		21
96	Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?. <b>2018</b> , 13, 160-166		22
95	Antibody-dependent cellular cytotoxicity in HIV infection. <b>2018</b> , 32, 2439-2451		37
94	Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	26
93	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , <b>2018</b> , 9, 1928	17.4	46
92	Immune Correlate-Guided HIV Vaccine Design. <b>2018</b> , 24, 25-33		34
91	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. <b>2018</b> , 9,		56
90	Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. <b>2018</b> , 11, 1716-1726		9
89	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <b>2018</b> , 174, 938-952.e13		126
88	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1006987	7.6	49

87	Human Immunodeficiency Virus Vaccines. <b>2018</b> , 400-429.e25		
86	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	8
85	Moving the HIV vaccine field forward: concepts of protective immunity. <b>2019</b> , 6, e406-e410		1
84	Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1512	8.4	2
83	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <b>2019</b> , 26, 336-346.e3		43
82	Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 697	8.4	32
81	VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 3163	8.4	13
80	Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	2
79	Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	5
78	Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability. <b>2018</b> , 16, 404-415		1
77	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1025	8.4	22
76	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	9
75	Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 332	8.4	72
74	HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells. <b>2019</b> , 27, 572-585.e7		9
73	Identification of HIV gp41-specific antibodies that mediate killing of infected cells. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007572	7.6	21
72	IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1008064	7.6	25
71	Antibody-dependent cellular cytotoxicity targeting CD4-inducible epitopes predicts mortality in HIV-infected infants. <b>2019</b> , 47, 257-268		5
70	HIV-1 antibodies in prevention of transmission. <b>2019</b> , 14, 273-278		8

69	Neutralizing antibodies for HIV-1 prevention. <b>2019</b> , 14, 318-324		23
68	Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1. <b>2019</b> , 35, 169-184		1
67	Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice. <b>2020</b> , 8,		0
66	Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1. <b>2020</b> , 16, 2033-2041		2
65	Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection. <b>2020</b> , 34, 1313-1323		4
64	Nanosystems Applied to HIV Infection: Prevention and Treatments. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
63	Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1744	8.4	1
62	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , <b>2020</b> , 5, 36	9.5	5
61	Curing HIV: Seeking to Target and Clear Persistent Infection. <b>2020</b> , 181, 189-206		48
60	Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. <b>2021</b> , 16, 1-14		59
59	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <b>2021</b> , 206, 1266-1283		3
58	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. <b>2021</b> , 223, 22-31		4
57	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , <b>2021</b> , 6, 56	9.5	4
56	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.		
55	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 678511	8.4	4
54	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. <b>2021</b> , 35, 109167		3
53	Photoinduced Photosensitizer-Antibody Conjugates Kill HIV Env-Expressing Cells, Also Inactivating HIV. <b>2021</b> , 6, 16524-16534		1
52	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , <b>2021</b> , 95, e0021921	6.6	0

51	Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 697683	8.4	1
50	Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG. <i>Retrovirology</i> , <b>2021</b> , 18, 23	3.6	0
49	HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 733958	8.4	1
48	The unmutated common ancestor of Gp41 conformational epitope targeting variable heavy chain 1-02 utilizing antibodies maintains antibody dependent cell cytotoxicity.		
47	Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. <b>2021</b> , 206, 999-1012		4
46	Frequencies of circulating Th1-biased T follicular helper cells in acute HIV-1 infection correlate with the development of HIV-specific antibody responses and lower set point viral load.		1
45	Optimized Mucosal MVA Prime/ Soluble gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen.		1
44	Flow virometric sorting and analysis of HIV quasispecies from plasma. <b>2017</b> , 2, e90626		11
43	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <b>2017</b> , 2,		8
42	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <b>2019</b> , 129, 1314-1328		23
41	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <b>2019</b> , 129, 4838-4849		55
40	Harnessing the protective potential of HIV-1 neutralizing antibodies. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	4
39	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179597	3.7	20
38	Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0180245	3.7	10
37	Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005619	7.6	70
36	HIV-1/SIV Humoral Responses in External Secretions. <i>Current Immunology Reviews</i> , <b>2019</b> , 15, 49-62	1.3	1
35	Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys.		
34	Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection pressure in fetuses.		

33	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. <i>Retrovirology</i> , <b>2021</b> , 18, 35	3.6	2
32	Detection of the HIV-1 accessory proteins Nef and Vpu by flow cytometry represents a new tool to study their functional interplay within a single infected CD4+ T cell.		
31	Neutralization and beyond: Antibodies and HIV-1 acquisition. <b>2018</b> , 15, 73-86		1
30	Engaging innate immunity in HIV-1 cure strategies. <i>Nature Reviews Immunology</i> , <b>2021</b> ,	36.5	2
29	ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1010046	7.6	3
28	Detection of the HIV-1 accessory proteins Nef and Vpu by flow cytometry represents a new tool to study their functional interplay within a single infected CD4+ T cell.. <i>Journal of Virology</i> , <b>2022</b> , jvi0192921	6.6	1
27	Latency Reversal and Clearance of Persistent HIV Infection.. <i>Methods in Molecular Biology</i> , <b>2022</b> , 2407, 375-389	1.4	
26	The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	0
25	Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 787603	8.4	
24	Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates.. <i>Vaccines</i> , <b>2022</b> , 10,	5.3	0
23	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010183	7.6	2
22	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines.. <i>Nature Communications</i> , <b>2022</b> , 13, 903	17.4	0
21	HIV-1 Vpu restricts Fc-mediated effector functions in vivo.		0
20	Conformational plasticity of the HIV-1 gp41 immunodominant region is recognized by multiple non-neutralizing antibodies.. <i>Communications Biology</i> , <b>2022</b> , 5, 291	6.7	0
19	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.. <i>Journal of Experimental Medicine</i> , <b>2022</b> , 219,	16.6	1
18	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.. <i>Journal of Virology</i> , <b>2022</b> , e0003422	6.6	1
17	Data_Sheet_1.xlsx. <b>2020</b> ,		
16	Data_Sheet_2.docx. <b>2020</b> ,		



15 Image\_1.TIF. 2019,

14 Image\_2.TIF. 2019,

13 Image\_3.TIF. 2019,

12 Image\_4.TIF. 2019,

11 Table\_1.XLSX. 2019,

10 Table\_2.XLSX. 2019,

9 Table\_3.XLSX. 2019,

8 Table\_4.XLSX. 2019,

7 Image\_1.JPEG. 2019,

6 Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. *Npj Vaccines*, 2022, 7, 53 9.5 0

5 Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2. *Vaccine*, 2022, 40, 4174-4181<sup>1</sup>

4 Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity. *Archives of Virology*, 2.6 1

3 HIV-1 Vpu restricts Fc-mediated effector functions in vivo. 2022, 41, 111624 0

2 Parameter estimation and identifiability analysis for a bivalent analyte model of monoclonal antibody-antigen binding. 0

1 H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials. 14, 0